Biotech stocks debated: Abivax, Ose and Nanobiotix divide investors
French biotech stocks spark lively debate among investors with contrasting views on Abivax, Ose Immuotherapeutics and Nanobiotix.
Published 7sem1 sourceImportantupdated 5j
Lire en français
≈ 24s
The fact
Nanobiotix records a 30% decline from peaks, while other biotech stocks show mixed technical signals and support levels to watch.
Investors hesitate facing inherent uncertainty in clinical trials and regulatory approvals in this volatile sector.
Click the link to read an article on the topic:
Story timeline
Jun 2Biotech stocks debated: Abivax, Ose and Nanobiotix divide investorsthis article